Theravance Biopharma, Inc. Income (Loss) from Equity Method Investments
Theravance Biopharma, Inc. (TBPH) reported Income (Loss) from Equity Method Investments of $28.13 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2022-08-08
- Theravance Biopharma, Inc. income (loss) from equity method investments for the quarter ending 2022-06-30 was $28.13M, a 28.28% increase year-over-year.
- Theravance Biopharma, Inc. income (loss) from equity method investments for the quarter ending 2022-03-31 was $25.11M, a 51.75% increase year-over-year.
- Theravance Biopharma, Inc. income (loss) from equity method investments for the quarter ending 2021-12-31 was $35.31M, a 75.31% increase year-over-year.
- Theravance Biopharma, Inc. income (loss) from equity method investments for the quarter ending 2021-09-30 was $30.21M, a 125.38% increase year-over-year.
- Theravance Biopharma, Inc. income (loss) from equity method investments for fiscal 2021 was $103.99M, a 51.94% increase from fiscal 2020.
- Theravance Biopharma, Inc. income (loss) from equity method investments for fiscal 2020 was $68.44M, a 103.05% increase from fiscal 2019.
- Theravance Biopharma, Inc. income (loss) from equity method investments for fiscal 2019 was $33.70M, a 201.42% increase from fiscal 2018.
- Theravance Biopharma, Inc. income (loss) from equity method investments for fiscal 2018 was $11.18M, a 6477.65% increase from fiscal 2017.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2022-06-30 | $28.13M 10-Q · filed 2022-08-08 | $53.24M 10-Q · filed 2022-08-08 | $88.54M derived: sum of 3 quarters · filed 2022-08-08 | $118.75M derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $25.11M 10-Q · filed 2022-05-06 | $60.42M derived: sum of 2 quarters · filed 2022-05-06 | $90.62M derived: sum of 3 quarters · filed 2022-05-06 | $112.55M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-12-31 | $35.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $65.51M derived: sum of 2 quarters · filed 2022-02-28 | $87.44M derived: sum of 3 quarters · filed 2022-08-08 | $103.99M 10-K · filed 2022-02-28 |
| 2021-09-30 | $30.21M 10-Q · filed 2021-11-08 | $52.13M derived: sum of 2 quarters · filed 2022-08-08 | $68.68M 10-Q · filed 2021-11-08 | $88.82M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-06-30 | $21.93M 10-Q · filed 2022-08-08 | $38.47M 10-Q · filed 2022-08-08 | $58.61M derived: sum of 3 quarters · filed 2022-08-08 | $72.02M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $16.55M 10-Q · filed 2022-05-06 | $36.69M derived: sum of 2 quarters · filed 2022-05-06 | $50.09M derived: sum of 3 quarters · filed 2022-05-06 | $71.47M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $20.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $33.54M derived: sum of 2 quarters · filed 2022-02-28 | $54.92M derived: sum of 3 quarters · filed 2022-02-28 | $68.44M 10-K · filed 2022-02-28 |
| 2020-09-30 | $13.40M 10-Q · filed 2021-11-08 | $34.78M derived: sum of 2 quarters · filed 2021-11-08 | $48.30M 10-Q · filed 2021-11-08 | $60.21M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $21.38M 10-Q · filed 2021-08-05 | $34.90M 10-Q · filed 2021-08-05 | $46.81M derived: sum of 3 quarters · filed 2022-02-28 | $54.01M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $13.52M 10-Q · filed 2021-05-06 | $25.43M derived: sum of 2 quarters · filed 2022-02-28 | $32.63M derived: sum of 3 quarters · filed 2022-02-28 | $40.99M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $11.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $19.11M derived: sum of 2 quarters · filed 2022-02-28 | $27.48M derived: sum of 3 quarters · filed 2022-02-28 | $33.70M 10-K · filed 2022-02-28 |
| 2019-09-30 | $7.20M 10-Q · filed 2020-11-09 | $15.56M derived: sum of 2 quarters · filed 2020-11-09 | $21.79M 10-Q · filed 2020-11-09 | $27.22M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $8.37M 10-Q · filed 2020-08-10 | $14.60M 10-Q · filed 2020-08-10 | $20.02M derived: sum of 3 quarters · filed 2021-02-26 | $23.14M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $6.23M 10-Q · filed 2020-05-08 | $11.66M derived: sum of 2 quarters · filed 2021-02-26 | $14.78M derived: sum of 3 quarters · filed 2021-02-26 | $16.73M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $5.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $8.55M derived: sum of 2 quarters · filed 2021-02-26 | $10.50M derived: sum of 3 quarters · filed 2021-02-26 | $11.18M 10-K · filed 2021-02-26 |
| 2018-09-30 | $3.12M 10-Q · filed 2019-11-08 | $5.07M derived: sum of 2 quarters · filed 2019-11-08 | $5.75M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $1.95M 10-Q · filed 2019-08-05 | $2.63M 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $686.00K 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $170.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |